Page last updated: 2024-09-05

erlotinib hydrochloride and shikonin

erlotinib hydrochloride has been researched along with shikonin in 2 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (shikonin)	Trials (shikonin)	Recent Studies (post-2010) (shikonin)
4,353	786	3,033	660	2	505

Protein Interaction Comparison

Protein	Taxonomy	shikonin (IC50)
Epidermal growth factor receptor	Homo sapiens (human)	0.1392
DNA topoisomerase 2-alpha	Homo sapiens (human)	6.6
Pyruvate kinase PKM	Homo sapiens (human)	6.2933
M-phase inducer phosphatase 1	Homo sapiens (human)	0.22
M-phase inducer phosphatase 2	Homo sapiens (human)	0.4
DNA topoisomerase 2-beta	Homo sapiens (human)	6.6
Class A sortase SrtA	Staphylococcus aureus	2.65

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bauer, R; Efferth, T; Kretschmer, N; Zhao, Q	1
Ding, K; Hu, X; Li, QY; Li, YL; Lin, NM; Tan, BQ; Wang, F; Zhang, B; Zhang, C	1

Other Studies

2 other study(ies) available for erlotinib hydrochloride and shikonin

Article	Year
Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. International journal of cancer, 2015, Sep-15, Volume: 137, Issue:6 Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mitogen-Activated Protein Kinases; Naphthoquinones; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction	2015
Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy. Molecular medicine reports, 2018, Volume: 18, Issue:4 Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lithospermum; Lung Neoplasms; Mice, Nude; Naphthoquinones; Protein Kinase Inhibitors; Reactive Oxygen Species	2018

Article

Year

Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.

International journal of cancer, 2015, Sep-15, Volume: 137, Issue:6

Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mitogen-Activated Protein Kinases; Naphthoquinones; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction

2015

Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.

Molecular medicine reports, 2018, Volume: 18, Issue:4

Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lithospermum; Lung Neoplasms; Mice, Nude; Naphthoquinones; Protein Kinase Inhibitors; Reactive Oxygen Species

2018